Search results
Neurogene reports initial data from Rett syndrome gene therapy trial
Clinical Trials Arena via Yahoo Finance· 12 hours agoNeurogene has shared initial safety and tolerability results from its ongoing Phase I/II clinical...
Neurogene reports safe gene therapy trial for Rett syndrome By Investing.com
Investing.com· 1 day agoNeurogene Inc. (NASDAQ: NGNE), a clinical-stage biotech company, has announced initial safety...
New findings activate a better understanding of Rett syndrome's causes
Medical Xpress· 6 days agoRett syndrome is caused by mutations to the gene MECP2, which is highly expressed in the brain and appears to play important roles in maintaining healthy ...
BERGER MONTAGUE PC ANNOUNCES THE FILING OF A CLASS ACTION COMPLAINT TO RECOVER LOSSES FOR INVESTORS...
WRBL Columbus· 3 hours agoBerger Montague PC has filed a class action lawsuit on behalf of investors who purchased securities of Anavex Life Sciences Corporation ("Anavex" or the "Company") (NASDAQ: AVXL) from June 21 ...
Nanny camera captures Utah man repeatedly raping severely disabled stepdaughter
KUTV Salt Lake City· 6 days agoPaula took care of her daughter, Ashley Vigil, who suffered from a rare genetic disorder known as ...
Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th,...
Morningstar· 6 days agoManagement will host a conference call on...
Candidates and voting rules for Virginia’s 2024 congressional primaries
WRIC 8 News Richmond· 2 days agoVirginians can vote in the U.S. congressional primaries, contests that will set matchups in key...
Neurogene (NASDAQ:NGNE) Earns Outperform Rating from Leerink Partnrs
ETF DAILY NEWS· 7 days agoLeerink Partnrs reaffirmed their outperform rating on shares of Neurogene (NASDAQ:NGNE – Free Report) in a report issued on Monday morning, Zacks.com reports. Other research analysts have also ...
Anavex Life Sciences investors: Please contact the Portnoy Law Firm to recover your losses; May 13,...
Benzinga· 7 days agoLOS ANGELES, May 01, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Anavex Life Sciences Corp. (NASDAQ:AVXL) investors that a lawsuit was filed on behalf of investors that purchased Anavex securities between
Neurogene Inc. (NASDAQ:NGNE) Expected to Earn Q1 2024 Earnings of ($1.19) Per Share
ETF DAILY NEWS· 6 days agoNeurogene Inc. (NASDAQ:NGNE – Free Report) – Research analysts at Leerink Partnrs issued their Q1 2024 earnings estimates for shares of Neurogene in a research report issued on Monday, April ...